Eq 300 dosage

¶ Dose reduction and/or serum Theophylline concentration measurement is indicated whenever adverse effects are present, physiologic abnormalities that can reduce Theophylline clearance occur (., sustained fever), or a drug that interacts with Theophylline is added or discontinued (see WARNINGS ).

Once-Daily Dosing: The slow absorption rate of this preparation may allow once-daily administration in adult non-smokers with appropriate total body clearance and other patients with low dosage requirements. Once-daily dosing should be considered only after the patient has been gradually and satisfactorily titrated to therapeutic levels with q12h dosing. Once-daily dosing should be based on twice the q12h dose and should be initiated at the end of the last q12h dosing interval. The trough concentration (C min ) obtained following conversion to once-daily dosing may be lower (especially in high clearance patients) and the peak concentration (C max­ ) may be higher (especially in low clearance patients) than that obtained with q12h dosing. If symptoms recur, or signs of toxicity appear during the once-daily dosing interval, dosing on the q12h basis should be reinstituted. 

It is essential that serum Theophylline concentrations be monitored before and after transfer to once-daily dosing.

Food and posture, along with changes associated with circardien rhythm, may influence the rate of absorption and / or clearance rates of Theophylline from extended-release dosage forms administered at night. The exact relationship of these and other factors to nighttime serum concentrations and the clinical significance of such findings require additional study. Therefore, it is not recommended that Theophylline extended-release once-daily dosing be administered at night.

Our extensive range of finished dosage formulations covers every aspect of human life. Our basket of formulations contain more than 850 products in several forms belonging to 45 therapeutic segments and 12 specialities including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics, immunogicals and oncology. The manufacturing expertise is available for almost all dosage forms including sterile as well as non sterile products. Formulations has three manufacturing facility in the state of Gujarat, Jammu (India) and Ethiopia. All of which are approved by all prominent international regulatory bodies, including USFDA

Eq 300 dosage

eq 300 dosage

Media:

eq 300 dosageeq 300 dosageeq 300 dosageeq 300 dosageeq 300 dosage